EGFR and lung adenocarcinoma: However, comprehensive real-world evidence specifically evaluating the efficacy and safety of this double-dose icotinib regimen (750 mg/day) as first-line therapy for patients with locally advanced or metastatic EGFR-mutant lung adenocarcinoma, especially in broader molecular subgroups (including both 19del and L858R) and high-risk populations (e.g., older adults, poor PS), remains limited.